Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cambridge Cognition Holdings Plc (COG.L)
Cambridge, GB
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +8.82% | +4.23% | -14.94% | +17.46% | +32.14% | -1.33% | -62.99% | -69.66% | -6.31% | -53.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | +2 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%-9.1% Q4'25: -32.0% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+16.5% Q4'25: -150.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-9.9% Q4'25: +4.0% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-16.5% Q4'25: -12.7% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%-56.6% Q4'25: -95.0% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+12.2% Q4'25: +35.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-0.91× Q4'25: -0.62× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.15M
est: 4.06M (+2.2%)
|
5.80M
est: 5.58M (+3.9%)
|
5.04M
est: 5.00M (+0.8%)
|
6.88M
est: 7.10M (-3.2%)
|
6.73M
est: 6.70M (+0.4%)
|
6.13M
est: 6.00M (+2.2%)
|
5.04M
est: 5.00M (+0.8%)
|
6.74M
est: 6.70M (+0.6%)
|
10.09M
est: 10.10M (-0.1%)
|
12.61M
est: 12.60M (+0.1%)
|
13.52M
est: 13.08M (+3.3%)
|
10.34M
est: 10.04M (+3.0%)
|
9.40M
est: 9.40M (+0.0%)
|
11.61M
11.10M – 12.13M
+23.5% YoY
|
14.19M
12.48M – 17.08M
+22.2% YoY
|
19.10M
17.46M – 21.62M
+34.6% YoY
|
| EBITDA |
-2.92M
est: -260.6K (-1,018.5%)
|
-266.0K
est: -351.3K (+24.3%)
|
-811.0K
est: -321.0K (-152.7%)
|
184.0K
est: -1.14M (+116.2%)
|
-207.0K
est: 223.5K (-192.6%)
|
-1.43M
est: -385.2K (-271.5%)
|
-2.95M
est: -1.19M (-147.5%)
|
-502.0K
est: -430.1K (-16.7%)
|
412.0K
est: -4.25M (+109.7%)
|
-514.0K
est: -5.11M (+89.9%)
|
-2.62M
est: -911.9K (-187.7%)
|
-542.0K
est: -700.0K (+22.6%)
|
-960.0K
est: -655.4K (-46.5%)
|
-809.4K
-845.6K – -773.9K
-23.5% YoY
|
-989.3K
-1.19M – -870.1K
-22.2% YoY
|
-1.33M
-1.51M – -1.22M
-34.6% YoY
|
| EBIT |
-2.96M
est: -383.8K (-669.9%)
|
-304.0K
est: -517.4K (+41.2%)
|
-867.0K
est: -472.7K (-83.4%)
|
116.0K
est: -1.22M (+109.5%)
|
-284.0K
est: 110.8K (-356.3%)
|
-1.49M
est: -567.2K (-162.3%)
|
-3.11M
est: -1.24M (-151.0%)
|
-640.0K
est: -633.4K (-1.0%)
|
264.0K
est: -4.49M (+105.9%)
|
-608.0K
est: -5.39M (+88.7%)
|
-3.29M
est: -1.42M (-131.7%)
|
-1.16M
est: -1.09M (-6.6%)
|
-1.55M
est: -1.02M (-52.0%)
|
-1.26M
-1.32M – -1.20M
-23.5% YoY
|
-1.54M
-1.85M – -1.35M
-22.2% YoY
|
-2.07M
-2.35M – -1.90M
-34.6% YoY
|
| Net Income |
-2.86M
est: -6.05M (+52.7%)
|
-173.0K
est: -2.01M (+91.4%)
|
-782.0K
est: -1.16M (+32.5%)
|
272.0K
est: -1.10M (+124.8%)
|
-257.0K
est: 259.8K (-198.9%)
|
-1.44M
est: -2.47M (+41.7%)
|
-2.90M
est: -4.09M (+29.2%)
|
-438.0K
est: -347.6K (-26.0%)
|
450.0K
est: -4.18M (+110.8%)
|
-409.0K
est: -3.74M (+89.1%)
|
-3.51M
est: -1.68M (-109.2%)
|
-1.79M
est: -1.18M (-50.8%)
|
-1.68M
est: -1.43M (-17.3%)
|
-257.4K
-482.5K – -32.3K
+82.0% YoY
|
753.3K
-526.7K – 2.03M
+392.7% YoY
|
2.08M
1.85M – 2.44M
+176.3% YoY
|
| SGA |
6.76M
est: 2.65M (+154.9%)
|
5.58M
est: 3.65M (+53.1%)
|
5.62M
est: 3.27M (+72.1%)
|
5.86M
est: 4.64M (+26.3%)
|
6.49M
est: 5.60M (+15.9%)
|
6.75M
est: 3.92M (+72.2%)
|
5.23M
est: 3.27M (+60.0%)
|
4.51M
est: 4.38M (+3.0%)
|
5.87M
est: 10.10M (-41.8%)
|
8.09M
est: 12.12M (-33.2%)
|
9.12M
est: 8.50M (+7.3%)
|
7.23M
est: 6.52M (+10.8%)
|
6.13M
est: 6.11M (+0.3%)
|
7.54M
7.21M – 7.88M
+23.5% YoY
|
9.22M
8.11M – 11.10M
+22.2% YoY
|
12.41M
11.34M – 14.05M
+34.6% YoY
|
| EPS |
-0.21
est: -0.16 (-34.1%)
|
-0.01
est: -0.05 (+80.1%)
|
-0.05
est: -0.03 (-55.1%)
|
0.01
est: 0.01 (+58.2%)
|
-0.01
est: 0.00 (-333.5%)
|
-0.07
est: -0.06 (-9.7%)
|
-0.12
est: -0.11 (-13.2%)
|
-0.01
est: -0.01 (-63.4%)
|
0.01
est: 0.01 (+12.9%)
|
-0.01
est: 0.00 (-408.3%)
|
-0.10
est: -0.04 (-166.4%)
|
-0.05
est: -0.03 (-74.4%)
|
-0.04
est: -0.03 (-20.7%)
|
-0.01
-0.01 – 0.00
+81.4% YoY
|
0.02
-0.01 – 0.05
+392.7% YoY
|
0.05
0.04 – 0.06
+176.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Baker | CEO, Joint MD & Senior Executive Director | 201.2K | male |
| James Ronald Openshaw | Chief Financial Officer, Head of Corporate Development & Director | 96.0K | male |
| John Hammond | Co-Founder | — | male |
| Nick Taptiklis | Head of Technology Strategy | — | male |
| Nicky Ackerley | Global HR Director | — | female |
| Simon McKeating | Company Secretary | — | — |
| Simon Merritt | Marketing and Communications Director | — | male |
| Barbara Sahakian FMedSci FBPsS | Senior Consultant | — | — |
| Trevor Robbins | Senior Consultant | — | — |
| Francesca Cormack | Chief Scientist & Member of Scientific Advisory Board | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COG.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
